COMMUNIQUÉS West-GlobeNewswire
-
FibroBiologics Presents Preclinical Data Demonstrating Durable Immunomodulation in Psoriasis at the Society for Investigative Dermatology 2026 Annual Meeting
22/05/2026 -
STORM Therapeutics to Present Promising Phase 1 Sarcoma Data Demonstrating Activity of First‑in‑Class METTL3 Inhibitor STC‑15 at ASCO 2026
22/05/2026 -
BioNTech to Showcase Progress Across Late-Stage Oncology Pipeline at the 2026 ASCO Annual Meeting
22/05/2026 -
China approves HERNEXEOS® as first targeted oral treatment option for HER2-mutant advanced NSCLC at initial diagnosis
22/05/2026 -
CROSSJECT announces the successful completion of an equity financing and warrant issuance for a total immediate gross amount of €15 million
22/05/2026 -
CROSSJCROSSJECT annonce le succès d’une augmentation de capital et d’une émission de bons de souscription d’actions (BSA) au profit d’investisseurs pour un montant de 15 millions d’euros
22/05/2026 -
OSE Immunotherapeutics Reports Positive Topline Results of TEDOVA Phase 2 Trial with Tedopi® in Recurrent Ovarian Cancer
22/05/2026 -
ANGEL Introduces X2 Water Filter System with Advanced Tankless 7-Stage Filtration and 99% PFAS Reduction
22/05/2026 -
Ex dividend NOK 1.00 today
22/05/2026 -
OSE Immunotherapeutics annonce les résultats de Topline positifs de l'étude de Phase 2 TEDOVA de Tedopi® dans le cancer de l’ovaire en rechute
22/05/2026 -
Most Effective Magnesium Pain Cream Researched: Real Magnesium Niacinamide Relief for Peak Health & Nerve Pain Recovery
22/05/2026 -
NervGen Announces Pricing of US$60.0 Million Public Offering of Securities
22/05/2026 -
FemiCore Claims Evaluated: Investigating the Ingredients for Bladder Support - Femi Core Consumer Complaints Exposed
22/05/2026 -
Medline Inc. announces pricing of upsized secondary offering of Class A common stock
22/05/2026 -
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026 -
Biogen and Denali Therapeutics Provide Update on Phase 2b LUMA Study of BIIB122 (DNL151) in Early-Stage Parkinson’s Disease
22/05/2026 -
TaiMed Biologics Completes Phase 2b Enrollment for TMB-365/380 in HIV Maintenance Therapy Study
22/05/2026 -
Liminatus Pharma Announces Nasdaq Delisting Notification
22/05/2026 -
Ascentage Pharma Releases Latest Clinical Data from Multiple Trials at ASCO 2026
22/05/2026
Pages